Nishant Rastogi

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.

Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, and low-side-effect therapies for idiopathic pain conditions. Our initial focus is on migraine, one of the most common neurologic disorders affecting over 1 billion people, with a high prevalence and morbidity, especially among adolescents and females. The company’s award-winning flagship Nerivio® REN wearable is changing the game for migraine sufferers, especially the 100 million adolescents facing this complex and non-curable disease. Nerivio is the first and only REN wearable that harnesses the natural power of the brain to shut off migraine symptoms without the use of drugs. With early intervention being key, Nerivio offers a safe and side-effect-free alternative, empowering adolescents to take control of their health and providing a foundation for complete migraine care as they transition into adulthood. Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, low-side-effect therapies for idiopathic pain conditions. The Nerivio REN wearable is FDA-cleared and CE-marked for the acute and/or preventive treatment of migraine with or without aura in people 8 years of age or older. It has been used in more than 650,000 migraine treatments in the US, including by adolescents and veterans living with migraine. Learn more by visiting our websites, theranica.com, and nerivio.com.

The most essential injectable medications today come from India and China. We’re changing that with our expanding pipeline of products made right here in America. American Injectables is a US-based sterile injectable manufacturer focused on ready-to-use pre-filled syringes and vials. The companys pipeline includes small molecule 505(b)(2) NDA and 505(j) ANDA syringe and vial products, and it serves as an outsourced contract manufacturing partner for strategic pharmaceutical companies.

Butterfly Medical is a medical-device start-up that aims to improve the standard of care for men suffering from Benign Prostate Hyperplasia (BPH) or enlarged prostate. The company has developed a fast, simple and minimally invasive alternative treatment to first-line BPH medication and surgery. Butterfly Medical’s patented device can be placed in under 10 minutes, in-office, under local anesthesia, without surgical incision, heating or prostate tissue removal. The device aims to be the only in-office BPH treatment that delivers a long-term, effective solution with minimal side effects, requiring no hospitalization or general anesthesia. Early results from clinical trials are very promising with blocked prostatic-urethras successfully opened and patients suffering no side effects. Further clinical studies are starting in leading medical centers in Europe. Visit www.butterfly-medical.com for more information.

Neuraptive is bringing novel therapeutic technology for the acute surgical repair of injured peripheral nerves.

GI Windows Surgical is a clinical-stage company engineering less invasive solutions for surgeons and patients.

InfoBionic’s MoMe® Kardia system empowers physicians with control to transform the efficiency with which they manage cardiac arrhythmia detection and monitoring processes for their patients. Leveraging a comprehensive, Cloud-based remote patient monitoring platform – the first and only of its kind – we deliver on-demand, actionable monitoring data and analytics directly to the physicians themselves. The MoMe® Kardia 3-in-1 device streams continuous ECG, respiration, and motion data to the Cloud for analysis, and delivers automated reporting to an iPad and or a web-based portal where physicians can access and interact with the data they need, in the detail they want – anytime, anywhere.

FineHeart is a clinical stage medical device company based in Bordeaux, France. Its innovative product, FLOWMAKER®, has the potential to treat 200,000 patients with advanced heart failure each year. FineHeart will initially target the 50,000 most severe patients who are eligible for cardiac assistance. Initial estimates value this market segment to be worth over US$5 billion. FineHeart was founded by CEO Arnaud Mascarell and a team of internationally renowned cardiac surgeons and electro-physiologists, including Dr. Stephane Garrigue, CSO and inventor of the concept, and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy (CRT). The company holds an international portfolio of 147 patents in 25 different families. FineHeart benefits from the support of a wide range of public, private, industrial and independent investors: including the French groups Lauak and Doliam, FineHeart Founders, as well as the investment funds and historical shareholders Aquiti, Broadview Ventures, Galia, Irdi , M Capital, NACO, UI Investment, & Verve Ventures. FineHeart is also financed by the European Union (EIC), Bpifrance and the Nouvelle Aquitaine and Région Centre regions. FLOWMAKER® is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the hearts natural contractions. It respects the natural blood flow and does not require aortic bypass surgery. It is the first miniaturized device - barely 10 cm in size - that is adjustable to patients needs, like a pacemaker, to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, which, on average lasts 90 minutes.

Lupus Ventures (dba “The Lupus Venture Fund”) is a venture capital fund dedicated to advancing treatment and diagnostic options for systemic lupus erythematosus (SLE), its manifestations, and related autoimmune conditions. We are a mission-driven firm and define success as improving the standard of care and delivering meaningful value to the millions of people living with lupus worldwide. The Fund is an affiliate of the Lupus Research Alliance (www.lupusresearch.org), the world’s largest private funder of lupus research. The Lupus Research Alliance has awarded more than $284 million across 650+ research grants, and clinical affiliate Lupus Therapeutics is involved in more than 25% of all active clinical trials.

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.

Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, and low-side-effect therapies for idiopathic pain conditions. Our initial focus is on migraine, one of the most common neurologic disorders affecting over 1 billion people, with a high prevalence and morbidity, especially among adolescents and females. The company’s award-winning flagship Nerivio® REN wearable is changing the game for migraine sufferers, especially the 100 million adolescents facing this complex and non-curable disease. Nerivio is the first and only REN wearable that harnesses the natural power of the brain to shut off migraine symptoms without the use of drugs. With early intervention being key, Nerivio offers a safe and side-effect-free alternative, empowering adolescents to take control of their health and providing a foundation for complete migraine care as they transition into adulthood. Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, low-side-effect therapies for idiopathic pain conditions. The Nerivio REN wearable is FDA-cleared and CE-marked for the acute and/or preventive treatment of migraine with or without aura in people 8 years of age or older. It has been used in more than 650,000 migraine treatments in the US, including by adolescents and veterans living with migraine. Learn more by visiting our websites, theranica.com, and nerivio.com.

The most essential injectable medications today come from India and China. We’re changing that with our expanding pipeline of products made right here in America. American Injectables is a US-based sterile injectable manufacturer focused on ready-to-use pre-filled syringes and vials. The companys pipeline includes small molecule 505(b)(2) NDA and 505(j) ANDA syringe and vial products, and it serves as an outsourced contract manufacturing partner for strategic pharmaceutical companies.

Butterfly Medical is a medical-device start-up that aims to improve the standard of care for men suffering from Benign Prostate Hyperplasia (BPH) or enlarged prostate. The company has developed a fast, simple and minimally invasive alternative treatment to first-line BPH medication and surgery. Butterfly Medical’s patented device can be placed in under 10 minutes, in-office, under local anesthesia, without surgical incision, heating or prostate tissue removal. The device aims to be the only in-office BPH treatment that delivers a long-term, effective solution with minimal side effects, requiring no hospitalization or general anesthesia. Early results from clinical trials are very promising with blocked prostatic-urethras successfully opened and patients suffering no side effects. Further clinical studies are starting in leading medical centers in Europe. Visit www.butterfly-medical.com for more information.